Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Year: 2018
Type: article
Abstract: Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.
Institutions: University of Pittsburgh, Emory University, Winship Cancer Institute, Memorial Sloan Kettering Cancer Center, National Cancer Institute, National Cancer Institute, National Cancer Institute, The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, University of Pennsylvania, Fred Hutch Cancer Center, Children's Hospital of Philadelphia, Stanford University, University of Chicago
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2903014927